Novel Agents Bosutinib and Ponatinib in CML and ALL: Results from the BELA and PACE Trials


Novel Agents Bosutinib and Ponatinib in CML and ALL: Results from the BELA and PACE Trials
Slides from presentations at ASH 2011 and transcribed comments from a recent interview with Srdan Verstovsek, MD, PhD (1/25/12)

Cortes JE et al. Initial findings from the PACE trial: A pivotal Phase 2 study of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. Proc ASH 2011;Abstract 109.

Cortes JE et al. Bosutinib versus imatinib in newly diagnosed chronic phase chronic myeloid leukemia — BELA trial: 24-month follow-up. Proc ASH 2011;Abstract 455.

Dr Verstovsek is Associate Professor, Chief of the Section of Myeloproliferative Neoplasms and Director of the Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center in Houston, Texas.